Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,463.00    0.00 (0.00%)
Bid:
1,100.00
Ask:
2,200.00
Spread: 1,100.00 (100.00%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Stabilisation Notice

31 Mar 2015 15:27

RNS Number : 0377J
Citigroup Global Markets Limited
31 March 2015
 

31st March 2015

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Hikma Pharmaceuticals PLC

Stabilisation Notice

Citigroup Global Markets Limited. (contact: Syndicate Desk 0207 986 9000) hereby gives notice that the Stabilising Manager(s) named below may stabilise the offer of the following securities in accordance with Commission Regulation (EC) No. 2273/2003 implementing the Market Abuse Directive (2003/6/EC).

The securities:

Issuer:

Hikma Pharmaceuticals PLC

Guarantor (if any):

Aggregate nominal amount:

$ TBC

Description:

Reg S registered

Offer price:

TBC

Other offer terms

TBC

Stabilisation:

Stabilising Manager(s):

 Citigroup Global Markets Limited

 

Stabilisation period expected to start on:

1st April 2015

Stabilisation period expected to end no later than:

1st May 2015 (30 days after the proposed issue date of the securities)

Maximum size of over-allotment facility:

5% of the aggregate nominal amount stated above.

 

In connection with the offer of the above securities, the Stabilising Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilising Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement and the offer of the securities to which it relates are directed only at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State that has implemented Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the "Prospectus Directive") before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Prospectus Directive (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Directive), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Directive (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STAJBMITMBTJBFA
Date   Source Headline
6th Nov 20257:00 amRNSNovember Trading Statement
1st Oct 202511:45 amRNSBlock listing Interim Review
23rd Sep 20251:52 pmRNSDirector/PDMR Shareholding
17th Sep 20259:16 amRNSDirector/PDMR Shareholding
22nd Aug 202512:02 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
8th Aug 202512:59 pmRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSHalf-year Report
9th Jul 20259:00 amRNSNotice of Results
7th Jul 20259:16 amRNSPublication of Offering Circular
9th Jun 20253:33 pmRNSDirector/PDMR Shareholding
5th Jun 20252:05 pmRNSDirector/PDMR Shareholding
3rd Jun 20251:02 pmRNSDirector/PDMR Shareholding
29th May 20257:00 amRNSFitch upgrades Hikma to ‘BBB’
20th May 20252:49 pmRNSDirector/PDMR Shareholding
15th May 202512:00 pmRNSMedium-term Group guidance ahead of US site visit
8th May 20254:35 pmRNSDirector/PDMR Shareholding
8th May 202510:48 amRNSS&P upgrades Hikma to ‘BBB’
8th May 20258:21 amRNSSettlement agreement for Xyrem® US lawsuits
30th Apr 20251:21 pmRNSDirector/PDMR Shareholding
24th Apr 20253:55 pmRNSResult of AGM
24th Apr 20257:00 amRNSTrading Statement
10th Apr 20252:36 pmRNSDirector/PDMR Shareholding
8th Apr 20251:47 pmRNSDirector/PDMR Shareholding
1st Apr 20259:30 amRNSBlock listing Interim Review
19th Mar 202510:10 amRNSAnnual Financial Report and Notice of AGM
4th Mar 202511:16 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSFinal Results
10th Feb 20258:09 amRNSNotice of Results
23rd Dec 20249:46 amRNSDirector/PDMR Shareholding
7th Nov 20243:30 pmRNSOutcome of Audit Tender Process
7th Nov 20247:00 amRNSTrading Statement
24th Oct 20247:00 amRNS2024 Annual General Meeting Update Statement
1st Oct 20249:45 amRNSBlock listing Interim Review
24th Sep 202410:09 amRNSDirector/PDMR Shareholding
10th Sep 20247:00 amRNSHikma completes Xellia acquisition
13th Aug 20249:39 amRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
29th Jul 20244:08 pmRNSDirector Declaration
15th Jul 20247:00 amRNSNotice of Results
1st Jul 20242:47 pmRNSTotal Voting Rights
27th Jun 20241:47 pmRNSDirector Declaration
17th Jun 20247:00 amRNSHikma acquires Xellia’s assets
5th Jun 20242:53 pmRNSDirector/PDMR Shareholding
9th May 20249:49 amRNSDirector/PDMR Shareholding
25th Apr 20242:28 pmRNSResult of AGM
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.